**** Read the official press release on Businesswire here ****
August 12, 2025, Orem, Utah — Techcyte, a leading provider of AI-powered digital diagnostics for anatomic and clinical pathology, today announced that its platform, Techcyte Fusion™ (research use only (RUO) in the US, CE-IVDD-marked in Europe), now includes Modella AI, a biomedical artificial intelligence company at the forefront of computational pathology, as a partner in the Techcyte Fusion Partner Program. This collaboration brings together Modella AI’s groundbreaking research-use only AI co-pilot for pathologists, PathChat™, with Techcyte’s integrated, cloud-based digital pathology platform—supporting the advancement of workflow efficiency and expanding access to advanced AI-powered pathology tools for research.
Modella AI is a biomedical artificial intelligence company focused on improving pathology through generative and agentic AI. Its flagship research product, PathChat, enables intelligent interactions with digital slides—offering capabilities such as report summarization, image interpretation, and contextual question answering.
An advanced research-use only version of the tool, PathChat DX, has been granted U.S. Food and Drug Administration Breakthrough Device Designation, reflecting the device’s potential to provide a more effective diagnosis of a life-threatening or irreversibly debilitating condition. While this designation recognizes the potential of the technology, any use of PathChat within the Techcyte Fusion platform remains for research use only and is not intended for clinical diagnostic purposes.
“Modella AI’s commitment to innovation, including agentic AI, and Techcyte’s unified pathology platform create a powerful research combination,” said Matt Smith, Chief Strategy Officer at Techcyte. “Together, our goal is delivering practical AI that pathologists can trust and that seamlessly integrates into their digital workflows.”
“We’re excited to partner with Techcyte to bring our pathology-native AI to a broader research audience,” said Jill Stefanelli, President, Cofounder, and Chief Executive Officer at Modella AI. “Integrating PathChat into the Fusion research platform supports the exploration of AI-assisted workflows in pathology and reflects our shared commitment to advancing digital innovation in the lab.”
The integration of PathChat into Techcyte Fusion represents a significant step forward in operationalizing next-generation AI. As pathology workloads increase and case complexity grows, this collaboration represents an important step toward exploring AI capabilities in digital pathology research settings—all within the familiar Techcyte platform.
For more information about the Techcyte Fusion Partner Program, visit www.techcyte.com.
###
About Modella
Modella AI (www.modella.ai) is a Boston-based biomedical AI company dedicated to advancing healthcare through the development of cutting-edge generative and agentic AI technologies. By combining expertise in artificial intelligence and pathology, Modella AI aims to deliver innovative solutions that empower clinicians, improve patient outcomes, and transform medical workflows.